BioVersys AG announced the publication of two Phase 1 clinical pharmacology studies of BV100, its lead antibiotic candidate, in the International Journal of Antimicrobial Agents and the Journal of Antimicrobial Chemotherapy. The data are significant because they address critical pharmacological questions for an intravenous antibiotic intended to treat severely ill patients with hospital- or ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC), a pathogen with limited treatment options and high mortality.
The lung penetration study, published in the International Journal of Antimicrobial Agents, enrolled 36 healthy male participants who received BV100 (intravenous rifabutin) 300 mg every 12 hours for four days. Concentrations of rifabutin in lung fluid and alveolar macrophages exceeded plasma concentrations at every time point, with median penetration ratios of approximately 35-fold and over 300-fold, respectively. Repeated dosing was well tolerated. The authors conclude that these pulmonary exposures provide a strong pharmacological rationale for further clinical evaluation of BV100 in severe CRAB pneumonia, where achieving adequate drug levels at the site of infection is essential. The full paper is available via 10.1016/j.ijantimicag.2026.108014.
The drug-drug interaction studies, published in the Journal of Antimicrobial Chemotherapy, show that BV100 is a mild CYP3A inducer, reducing midazolam exposure by approximately 47%, and a mild substrate for CYP3A inhibitors, with rifabutin exposure increasing 1.3- to 1.7-fold with itraconazole. This profile is milder than that of rifampicin, a strong CYP3A inducer, and BV100 was safe and well tolerated in both studies. The finding matters because critically ill pneumonia patients often receive multiple medications, and a milder interaction profile reduces the risk of clinically significant drug interactions. The paper can be accessed through DOI: 10.1093/jac/dkag317.
These Phase 1 datasets form part of the clinical pharmacology foundation of RIV-TARGET, the ongoing Phase 3 registration trial of BV100 in CRABC pneumonia. Enrollment is ongoing, with topline data anticipated in early 2028. BV100 is also being studied in the open-label Phase 2b differentiation trial, RIV-CARE, in collaboration with ADVANCE-ID. In September 2026, BV100 received Fast Track Designation from the US FDA under the Qualified Infectious Disease Product designation granted in 2019, which makes it eligible for priority review and a five-year extension of market exclusivity upon approval of the first QIDP indication. The publications and regulatory designations together strengthen the case for BV100 as a potential new option for CRABC pneumonia, where incidence and resistance rates are rising and treatment options remain scarce.
